- Home
- REVB vs SLRX Comparison
REVB vs SLRX Comparison
Compare REVB & SLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REVB
- SLRX
- Stock Information
- Founded
- REVB 2020
- SLRX N/A
- Country
- REVB United States
- SLRX United States
- Employees
- REVB N/A
- SLRX N/A
- Industry
- REVB Biotechnology: Pharmaceutical Preparations
- SLRX Biotechnology: Pharmaceutical Preparations
- Sector
- REVB Health Care
- SLRX Health Care
- Exchange
- REVB Nasdaq
- SLRX Nasdaq
- Market Cap
- REVB 2.2M
- SLRX 1.8M
- IPO Year
- REVB N/A
- SLRX N/A
- Fundamental
- Price
- REVB $0.86
- SLRX $0.72
- Analyst Decision
- REVB
- SLRX
- Analyst Count
- REVB 0
- SLRX 0
- Target Price
- REVB N/A
- SLRX N/A
- AVG Volume (30 Days)
- REVB 2.8M
- SLRX 23.3K
- Earning Date
- REVB 05-08-2025
- SLRX 05-14-2025
- Dividend Yield
- REVB N/A
- SLRX N/A
- EPS Growth
- REVB N/A
- SLRX N/A
- EPS
- REVB N/A
- SLRX N/A
- Revenue
- REVB N/A
- SLRX N/A
- Revenue This Year
- REVB N/A
- SLRX N/A
- Revenue Next Year
- REVB N/A
- SLRX N/A
- P/E Ratio
- REVB N/A
- SLRX N/A
- Revenue Growth
- REVB N/A
- SLRX N/A
- 52 Week Low
- REVB $0.77
- SLRX $0.45
- 52 Week High
- REVB $60.80
- SLRX $7.20
- Technical
- Relative Strength Index (RSI)
- REVB 20.22
- SLRX 41.78
- Support Level
- REVB $0.78
- SLRX $0.68
- Resistance Level
- REVB $1.15
- SLRX $0.80
- Average True Range (ATR)
- REVB 0.23
- SLRX 0.04
- MACD
- REVB -0.15
- SLRX -0.01
- Stochastic Oscillator
- REVB 3.38
- SLRX 8.93
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).
About SLRX Salarius Pharmaceuticals Inc.
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.